Arbutus to Present Imdusiran Data at EASL Congress 2024 [Financial Post (Toronto, Ontario, Canada)]
Arbutus Biopharma Corporation (ABUS)
Last arbutus biopharma corporation earnings: 11/6 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.arbutusbio.com/node/5806
Company Research
Source: Financial Post
WARMINSTER, Pa., May 22, 2024 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that two abstracts have been accepted for poster and oral presentations at the European Association for the Study of the Liver (EASL) Congress 2024 taking place June 5 – 8, 2024 in Milan, Italy. Article content The accepted abstracts for presentation are as follows: Article content Abstract Number: Presentation Type: Poster presentation Title: Imdusiran (AB-729) administered every 8 weeks in combination with 24 weeks of pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection leads to HBsAg loss in some subjects at end of IFN treatment. Presenter: Prof. Man-Fung Yuen Presentation Date: June 5, 2024 Key Findings
Show less
Read more
Impact Snapshot
Event Time:
ABUS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABUS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABUS alerts
High impacting Arbutus Biopharma Corporation news events
Weekly update
A roundup of the hottest topics
ABUS
News
- Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels [Yahoo! Finance]Yahoo! Finance
- Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B [Yahoo! Finance]Yahoo! Finance
- Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg LevelsGlobeNewswire
- Arbutus Biopharma Co. (NASDAQ: ABUS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.MarketBeat
ABUS
Earnings
- 5/2/24 - In-Line
ABUS
Sec Filings
- 6/10/24 - Form SC
- 6/6/24 - Form 8-K
- 6/5/24 - Form 8-K
- ABUS's page on the SEC website